Rajiv Anand, M.D.
NPI 1508865254 · Ophthalmology Physician · Dallas, TX
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1508865254
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- H5505 (TX)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
5,218 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Imaging of Retina92134 | 2,138 | $41 |
| Established Patient Complete Exam of Visual System92014 | 1,703 | $129 |
| Injection of Drug Into Eye67028 | 700 | $115 |
| New Patient Complete Exam of Visual System92004 | 257 | $153 |
| Established Patient Problem Focused Exam of Visual System92012 | 201 | $91 |
| 2d Ultrasound Scan of Eye Tissue and Structures76512 | 62 | $48 |
| Exam of Retinal Blood Vessels Using a Special Camera After Injection of a Dye |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 7 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 87 | 74 |
| Prednisolone Acetate | 74 | 58 |
| Ketorolac Tromethamine | 49 | 37 |
| Ofloxacin | 48 | 43 |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 33 | 20 |
| Latanoprost | 24 | 16 |
| Erythromycin Basebrand: Erythromycin | 12 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$822 across 12 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-07-15
- Last updated
- 2013-02-04
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.